MedTrace Logo

36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets

NCT02106442 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 579

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to evaluate the effectiveness (endpoints: frequency of bone fractures, percent change in bone density, etc.) and safety of administration of sodium risedronate tablets 75 mg for 36 months in osteoporosis patients in daily medical practice.

Conditions

Interventions

DRUG

Sodium risedronate

Sodium risedronate tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-13
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106442 on ClinicalTrials.gov